Previous 10 | Next 10 |
home / stock / imvt / imvt articles
Biohaven Ltd’s (NYSE:BHVN) shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV...
Shares of Bank of Montreal (NYSE:BMO) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter fi...
U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday. Shares of HEICO Corporation (NYSE:HEI) rose sharply dur...
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. KMX reported a t...
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of ba...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. Shares of Micron Technology, Inc...
Steelcase Inc. (NYSE: SCS) shares moved higher during Wednesday's session following quarterly results. Steelcase posted upbeat earnings for its...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. Shares of FedEx Corporation (NYSE: F...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...